A number of mechanisms limit the regenerative capacity of the injured adult mammalian CNS, including insufficient trophic support and the presence of inhibitors to axon growth associated with both myelin and the extracellular matrix 1, 2 . Among the extracellular matrix molecules that inhibit axon growth, a major contribution is made by chondroitin sulfate proteoglycans (CSPGs) 3, 4 . The predominant CSPG molecules present in the CNS include neural/glial antigen 2, neurocan and aggrecan [5] [6] [7] , which consist of a core protein with long, sulfated glycosaminoglycan side chains. The side chains are the primary determinants of axon inhibition 8 . As the period of robust developmental plasticity of the nervous system closes, CSPGs form around neurons and synapses in 'perineuronal nets' that are postulated to influence the function of the CNS by controlling plasticity and sprouting 9 . In addition, CSPGs are newly synthesized at sites of CNS injury and directly block axon growth [5] [6] [7] [8] [10] [11] [12] . The natural bacterial enzyme chondroitinase (Chase) ABC can degrade the inhibitory carbohydrate side chains on CSPGs 3, 4, 13, 14 . Indeed, Chase administration to rats after spinal cord injury (SCI) enhances growth of both corticospinal and sensory axons, and improves functional outcomes 3, 4, [14] [15] [16] . These growth-promoting effects of Chase result from the removal of perineuronal nets, which increases sprouting from spared axons below the injury site and formation of new synaptic connections 17, 18 . Alternatively, when a cellular or peripheral nerve bridge is placed into a spinal cord lesion site, Chase can promote axonal regeneration of cut axons into the bridge 10, 19 . Beneficial effects of Chase administration have been reported in rodent models of SCI 3, 4, 10, [14] [15] [16] 18, 20 , nigrostriatal injury 13 and stroke [21] [22] [23] , and cats with SCI 24, 25 . New therapies to promote CNS sprouting and regeneration are needed to improve outcomes after human neurotrauma and stroke. Given the replication of Chase efficacy across multiple experimental models by independent laboratories, together with the identification of compelling candidate mechanisms underlying its beneficial effects, we tested Chase therapy in a non-human primate model of SCI as a potential prelude to human clinical trials. Primates, both human and non-human, exhibit potentially important differences from rodents in terms of size, anatomy, systems function and immunology that make predictions of human safety and benefit based solely on rodent studies uncertain, a concern highlighted by numerous failed trials in stroke, SCI and other disorders [26] [27] [28] [29] . First, we employed a porcine model to test methods for Chase administration in the spinal cord of large animals, and found that intrathecal infusions failed to degrade CSPGs in spinal cord gray matter. Accordingly, we moved to intraparenchymal spinal cord injections of Chase; these effectively degraded CSPGs in our rhesus monkey model of C7 spinal cord lateral hemisection 30 . This experiment hypothesized that degradation of perineuronal nets surrounding neurons in spinal cord gray matter below the lesion would enhance sprouting of spared host axonal systems, including the corticospinal tract (CST), the most important motor system for voluntary movement in primates 31, 32 . Previously, we reported spontaneous sprouting of spared corticospinal axons in monkeys after C7 lesions 
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Results
Route of Chase administration: successful delivery by intraparenchymal but not intrathecal infusion. In a preliminary study, we determined whether intrathecal injections of Chase, a frequent and effective route of administration in rat studies, would effectively diffuse into the spinal cord of a larger animal. We used pigs for this study because their spinal cords measure roughly 8-11 mm in diameter (compared to the rat spinal cord width (3.5 mm) and the human spinal cord width (12.5 mm)). Seven adult American Yorkshire-Landrace-Duroc pigs received intermittent (every other day for 2 weeks) intrathecal injections of 2 ml of saline (n = 1), 5 U Chase enzyme ml −1 (5 U ml −1 , 10 U per dose; n = 3 animals; for Chase, 1 U is the amount that catalyzes the conversion of 1 μmol of chondroitin sulfate A or C per minute at 37 °C and pH 8.0), or 25 U Chase enzyme ml −1 (50 U per dose; n = 3 animals) (Chase provided by Acorda Therapeutics). Injections were made at 0.2 ml min −1 via an indwelling catheter into the intrathecal space between vertebrae T11-13. Pigs were killed 2 d after the last dose of intrathecal Chase. With this infusion method, 2B6 immunohistochemistry revealed degradation of glycosaminoglycan side chains in both low-and high-dose groups in a 1 mm rim of the superficial circumferential thoracic spinal cord white matter ( Supplementary Fig. 1a,b) . However, perineuronal nets in the spinal cord gray matter were not attenuated, as revealed by Wisteria floribunda agglutinin (WFA) lectin histochemistry ( Supplementary Fig. 1c,d ). Because a prime target of Chase therapy is removal of perineuronal inhibitory CSPGs in gray matter to enhance plasticity and new synapse formation, we concluded that intrathecal infusions of the current formulation of Chase in the larger spinal cord were not an effective delivery method to enable hypothesis testing in the primate model; thus, in the absence of a more parenchymal-penetrant formulation or method for Chase administration, we moved to intraparenchymal injections in monkeys.
In a preliminary study to test the delivery efficacy of intraparenchymal Chase administration in monkeys, two adult rhesus male monkeys underwent C7 spinal cord hemisection lesions 30, 35 , followed 4 weeks later by intraparenchymal injections of Chase. Four weeks post-lesion is a time point when spontaneous plasticity in primates is occurring. Monkeys received injections of 20 U ml −1 Chase starting at spinal cord level C7 (1 mm caudal to the lesion); 5 µl of Chase were injected at each of 10 sites, spaced 1.5 mm apart in the rostrocaudal axis, on the right side of the spinal cord from C7 to T1. Chase was infused at two dorsoventral depths per injection site, the first targeting the intermediate gray (2.5 mm depth) and the second targeting the ventral gray (3.5 mm depth); 2.5 µl were injected at each depth (infusion rate 0.5 µl ml ) for a total volume of 5 µl per site (Fig. 1) . As noted earlier, the primary objective of this injection design is to degrade perineuronal CSPG 'nets' that surround adult neurons in host gray matter below the lesion site, to enhance sprouting from spared host axons 10, 15, 18 that occurs spontaneously after SCI 30, [36] [37] [38] [39] [40] [41] . We did not attempt to promote regeneration into the lesion site by grafting cellular or peripheral nerve bridges into the lesion cavity 10, 14, 19 . Animals were transcardially perfused 2 weeks later to assess CSPG degradation by WFA histochemistry. CSPGs were completely degraded in the spinal cord gray matter over a distance of at least 2 mm from each injection site without evident damage to the spinal cord or neuronal loss ( Fig. 2 and Supplementary  Figs. 2-4) . Therefore, we used the same injection design to deliver Chase to the animals in the therapeutic efficacy study. CSPGs were also degraded at the caudal aspect of the C7 spinal cord lesion site ( Supplementary Fig. 5 ).
Chase therapeutic efficacy study in non-human primates
A total of 12 adult male rhesus monkeys underwent right-sided C7 complete spinal cord hemisection lesions, which result in persistent deficits in right hand dexterity but retention of bowel/bladder function and locomotion 30, 35, 39, 42 . While this lesion results in extensive impairment in right hand function immediately after the lesion, there is consistent and predictable, but incomplete recovery from 4 to 8 weeks post-lesion, with little further improvement thereafter 30, 35, 39, 42 . Hypothesizing that the period of recovery from 4 to 8 weeks is mediated by spontaneous anatomical plasticity, we injected Chase 4 weeks post-injury to target the enhancement of endogenous plasticity. This delay was also chosen because it is a clinically practical time to intervene after SCI, when most medical complications in humans have stabilized and patients are better candidates to undergo surgical intervention 43 . Moreover, the extent of functional deficit and probability of further spontaneous clinical recovery can be assessed more reliably in humans 4 weeks post-injury than within days of injury, which are considerations that are helpful in designing a clinical trial.
The primate C7 lesion model was designed to assess potential therapies for improving hand function, since neural circuitry for hand control is located in the C7-T1 spinal levels ranging from 1 to 15 mm below the lesion. These segments received intraparenchymal injections of Chase (20 U ml −1 ) 4 weeks after lesions were placed, as indicated earlier (Fig. 1) . Four days later, monkeys underwent daily half-hour exposure to a large testing enclosure enriched with numerous objects, perches and food rewards to encourage use of both fore and hind limbs 42, 44 . Monkeys engage in naturalistic and reward-driven behaviors in this environment 42, 44 . Once per week, several functions in the enclosure were evaluated and scored on an ordinal scale by an observer blinded to treatment condition 42, 44 . Some of these functional measures are sensitive to forelimb performance ( Supplementary Fig. 6 ), others to hind limb performance; yet other scores represent composites of overall function (Fig. 3) . Separately, monkeys underwent daily exposure to a cage-based Brinkman board task with graded levels of difficulty, requiring retrieval of small food items from baited wells using only the affected right arm (Fig. 3 ). There were five levels of difficulty on this task, and monkeys were scored weekly on each level. A total of 12 monkeys underwent C7 lesions: 6 received injections of Chase and 6 were lesioned controls. Of the lesioned controls, 4 monkeys received injections of 5 µl of saline per site, 1 underwent needle entry only into each site and 1 monkey underwent sham surgery to expose the spinal cord, without needle entry or saline injection. No differences were noted between these controls on any measured parameter; their data were combined in the subsequent analyses. Three months after Chase administration or control injections, animals underwent anterograde tracing of the corticospinal projection with biotinylated dextran amine (BDA) in the left hemisphere and dextran-conjugated Alexa Fluor 488 in the right hemisphere 45 , and were transcardially perfused 6 weeks later (5.5 months after the initial lesion). One control was excluded posthoc from the behavioral analyses on the basis of over-lesion that extended into the right side of the spinal cord (see Supplementary  Fig. 7 ). An additional control did not undergo corticospinal tracing due to weight drop below the minimum level required to allow surgery.
Chase administration improves functional outcomes
We performed a non-linear principal components analysis (PCA; see Methods) on the ensemble of all behavioral outcome data from the exercise enclosure and the Brinkman board ( Fig. 3 ; n = 6 Chase animals and n = 5 controls). Behavioral measures loaded highly on the first principal component (PC1), which accounted for 68% of the variance in recovery (Supplementary Fig. 8 ). The resulting weights for each measure were then extracted to create principal component scores for each animal at each time point. PC1 scores were then used to test for group differences in performance over time. Overall, PC1 showed a significant difference between lesioned controls and Chase-treated animals over time, favoring the Chase-treated group (condition × time, F (9, 23 .87) = 5.15, P = 0.001, Akaike information criterion (AIC) = 94.21, linear mixed model (LMM); Fig. 3a) . Lesioned control animals in this study followed a previously reported pattern (stated earlier) 30, 42 of marked impairment in function post-lesion, relative to their pre-lesion baseline, for the first 4 weeks after C7 hemisection (Fig. 3) . This was followed by spontaneous recovery of function (reflected by the PC1 scores) over weeks [5] [6] [7] [8] (Fig. 3a) . The function of lesioned controls did not significantly improve further from weeks 5-8 to weeks [17] [18] [19] [20] (Fig. 3j ). This observation is consistent with the delivery of Chase to spinal cord segments influencing hand function. In terms of absolute performance levels, monkeys that received Chase exhibited an overall final food object retrieval success rate of 47 ± 12% across all difficulties of the Brinkman board in the final testing period, compared to nearly 100% pre-injury performance, and an inability to retrieve objects in the first 4 weeks after injury. In comparison, lesioned control monkeys recovered to 31 ± 14% final food object retrieval on the Brinkman board, compared to 5 ± 3% performance in the first 4 weeks after injury. This is a 51% difference between groups in the extent of recovery, favoring Chase-treated animals. The difference in absolute performance between groups is significant (P = 0.014, LMM, condition × time, F (37, 12.48) = 3.26, AIC = 1461.5).
PCA also generated a second and third principal component that accounted for 10.5 and 5.1% variance, respectively ( Supplementary  Fig. 8 ). However, loading patterns for these components did not These individual task plots show that, although single functional outcome metrics may not be sensitive on their own, combining all metrics in a PCA reveals a robust effect of Chase treatment at the multivariate level. The object manipulation score (d) reflects use of the impaired forelimb to manipulate a large piece of fruit and retrieve food items from inside a Kong brand toy. Brinkman 1 through to Brinkman 5 (e-i) indicates progressively more difficult versions of food retrieval (see Methods; raw Brinkman scores are reported in the text). j, The locomotion score reflects use of the ipsilesional limbs for moving around the exercise enclosure. k, The climbing score reflects use of ipsilesional limbs for vertical climbing in the exercise enclosure. l, The general score is a composite of multiple measures that describe forelimb and hind limb function, as described in Nout et al. 42 and Salegio et al. 44 . Generally, the Chase-treated group exhibited superior recovery on tasks reflecting hand use (the spinal cord region targeted with Chase injections), and no difference in measures that included hind limb function (that is, those not targeted by Chase treatment). n = 6 Chase-treated animals and n = 5 controls. The large data points show the group means, the small data points are the individual animals, and the error bars represent the s.e.m.
indicate clearly definable eigenmodules; thus, scores on these components were not tested.
Chase administration improves anatomical outcomes
We hypothesized that, by degrading perineuronal nets in the gray matter surrounding neurons and synapses caudal to the C7 lesion site, Chase administration would increase axonal sprouting and synaptogenesis from spared axonal systems. Previously, we reported that, in rhesus monkeys, spared components of the corticospinal system that decussate across the spinal cord midline undergo spontaneous axonal sprouting after C7 hemisection lesions 30, 39 . In Chase-treated animals, we found greater total length (compared to controls) of corticospinal axons in gray matter caudal to the injury at C8, which is indicative of sprouting of spared corticospinal axons that decussate across the spinal cord midline 30, 39 (n = 6 Chase-treated animals and n = 5 controls; F (1, 30 .02) = 4.81, P = 0.036, AIC = 693.89, LMM; Fig. 4c ). The same Chase-associated increase in axon density (compared to controls) was observed in CST axons originating in the right motor cortex (F (1, 43.13) = 13.15, P = 0.001, AIC = 1239.11, LMM; Supplementary Fig. 9 ). All measures were made in a blinded fashion; analysis of corticospinal axons arising from the left hemisphere was done in one laboratory (M.H.T.), while analysis of axons arising from the right hemisphere was done independently in a second laboratory (J.W.F.).
In addition, Chase treatment was associated with a significant increase, compared to lesioned controls, in the number of corticospinal synapses in gray matter caudal to the injury (n = 6 Chase-treated animals and n = 5 controls; F (1, 38.12) = 12.06, P = 0.001, AIC = 119.18, LMM; Fig. 4 ). CST synaptic connectivity was assessed by quantifying the number of CST terminal boutons that colocalized with synaptophysin immunoreactivity, divided by the sampled volume of gray matter (Fig. 4e) .
We also assessed whether serotonergic axons respond to Chase treatment. In a previous study of lesioned animals lacking experimental treatment, serotonergic axons, in contrast to corticospinal axons, did not exhibit detectable sprouting after C7 hemisection lesions 30 . In the present study, we observed no difference between Chase-treated animals and controls in total serotonergic axon length in motor neuron pools caudal to SCI (n = 6 Chase-treated animals and n = 5 controls; Wald χ 2 = 0.009, quasi-likelihood under the independence model criterion (QIC) = 4.86, P = 0.924, generalized estimating equation; Supplementary Fig. 10 ). All anatomical measures were made by observers blinded to treatment group.
Safety
Anatomical analysis of injection sites with Nissl staining revealed no detectable toxicity after intraparenchymal spinal cord injections ( Supplementary Fig. 2 ). We also quantified motor neurons in a series of sections straddling an injection site in each monkey, and found no neuron loss in Chase-injected versus lesioned control monkeys (Supplementary Fig. 3 ). In addition, we quantified IBA1 immunolabeling in gray matter adjacent to the injection sites to assess microglial responses, and found no difference between Chase-injected, saline-injected and lesion control groups (ANOVA, F (2, 3.78) = 0.11, P = 0.89; Supplementary Fig. 4) . Moreover, cellular-mediated inflammation in gray matter, assessed by labeling for CD8, CD3 and CD45, was extremely mild 2 weeks after Chase injection (Supplementary Fig. 3 ; CD8 labeling shown). Labeling for CD8, CD3 and CD45 was no longer detectable 4.5 months after injections of either Chase or saline ( Supplementary Fig. 3 ). Systemically, Chase-treated and lesioned control monkeys exhibited no notable differences in weight, activity or post-lesion complications. Although formal pain tests were not employed, monkeys exhibited no behaviors that suggested pain (for example, reduced activity, enhanced startle).
Discussion
Chase treatment showed efficacy on both anatomical and functional outcome measures. On functional assays, effects were only suggested on forelimb measures, which were anatomically targeted by Chase injections into cervical segments mediating hand control, whereas effects were not evident on hind limb measures. Anatomically, Chase treatment significantly increased the length of corticospinal axons in cervical spinal cord segments below the lesion, representing sprouting of axons spared by the lesion, and also significantly increased the number of corticospinal terminals colocalizing with a synaptic marker, indicating a likely increase in the number of corticospinal synapses.
In contrast to studies in rats and cats 24 , the effects of Chase on serotonergic axons were not detected. Interestingly, serotonergic axons do not detectably sprout following C7 hemisection lesions in rhesus monkeys 30, 39 . A number of mechanisms could potentially account for this observation, including the possibility that serotonergic axons are highly branched and sustaining collaterals may minimize injury responses in the hemisection model 46 .
The overall functional success of food object retrieval on the Brinkman board task, a test of finger use, was 47 ± 12% among Chase-injected animals compared to 31 ± 14% in lesioned controls. Chase-treated animals also showed better recovery than lesioned controls on an object manipulation scale in the testing enclosure (21.25 point improvement versus 12.5 point improvement; Fig. 3d ). On anatomical measures, CST axon terminal innervation was 50% denser after Chase treatment (Fig. 4c ) and the number of putative synapses by corticospinal axons increased twofold compared to lesioned controls (Fig. 4e) . The reticulospinal system was not traced or quantified in this study. It is possible that, like the CST, reticulospinal axons might sprout in response to Chase treatment and mediate functional recovery.
We developed the non-human primate model of SCI to enable testing of potential translational therapies, invasive therapies in particular, before human translation. The rhesus monkey represents the most proximate animal model of the human nervous system that is experimentally testable. We have found that rhesus macaques exhibit variation in motivation, task engagement and response to injury that constitutes a source of variability exceeding that encountered in rodent models. This variability may result from the increased complexity of the rhesus brain compared to the rodent brain, and/or the considerable genetic differences in primates that exceed variation found even in outbred rat strains. Consequently, it is probable that this non-human primate model, while less variable than human injuries, incorporates some features of the variability typically encountered in the human clinical setting. Thus, the ability to detect significant differences on several measures following Chase administration, despite intersubject variability in this model, provides support for the initiation of human clinical trials. While the sample size in this study is small, the costs and duration of this work constitute a relative barrier to studying larger numbers of animals. Our use of data-driven multivariate statistical analysis before hypothesis testing allowed us to efficiently test recovery in ensemble across multiple tasks, thereby maximizing information gain with small n, while remaining sensitive to therapeutic effects 47 . Notably, multivariate statistics are not typically employed in clinical trials, which instead generally rely on one or two predefined outcome measures to establish clinical efficacy 48 . Interestingly, had we used classical univariate statistics in the present study, the functional benefit of Chase therapy would likely not have been appreciated. This raises the possibility that a treatment of potential functional benefit might be unappreciated in a clinical trial, despite the presence of a clear biological benefit at the level of axonal growth and synaptogenesis. This finding highlights the great importance of continued consideration and development of multivariate outcome measures in clinical trials, a point that is receiving increasing attention 49, 50 . There are important limitations to this non-human primate model of SCI. First, the injury itself is a hemisection, rather than a contusion, which is generally considered more representative of human injuries. In fact, we have developed a contusive model of SCI in a non-human primate, which could be employed in future preclinical studies 44 . Second, the C7 level of the hemisection SCI is optimally placed for recovery of hand function. New studies are required to assess the potential benefit to humans with higher cervical injuries or with thoracic injuries, although preceding rat SCI studies have demonstrated the functional benefits of Chase after C4 (refs. 14, 15 ) and thoracic 16 SCI. In addition to presenting evidence of efficacy, this study also preliminarily demonstrates that multiple parenchymal injections of Chase appear to be well tolerated. The outcome of the present study, taken together with the beneficial effects observed by many independent research groups in various rodent models of SCI, support the concept of translation of Chase treatment to human clinical trials.
The large-animal porcine model revealed that intrathecal infusions of the native Chase enzyme at even relatively high concentrations did not reach gray matter target regions. Thus, to advance these proof-of-concept studies into the clinically relevant primate model of SCI, we turned to more invasive intraparenchymal injections of Chase. The injections appeared to be well tolerated anatomically based on inflammatory markers and cell counts. Chemical modifications to Chase may enhance its penetrant properties after intrathecal administration, a possibility that merits further study for potential future clinical translation.
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Methods

Animals.
We studied a total of 14 rhesus macaques (Macaca mulatta, male, aged 6-10 years) and 7 pigs (American Yorkshire-Landrace-Duroc pigs, male, aged 4-6 months). With regard to power analysis, two of the macaques were used to establish the delivery efficacy of intraparenchymal Chase administration. The remaining 12 macaques were split into two groups of 6. At a standard deviation of 20% (an estimate drawn from our previous work) and effect size of 40%, n = 6 per group gives a computed power of 0.89, with α = 0.05. Power analyses were not performed for the preliminary porcine study of intrathecal Chase delivery. Porcine study. Spinal cord lesions were not made. All animals underwent intrathecal catheter placement at T11-13 and Chase (provided by Acorda Therapeutics) was infused through this indwelling catheter every other day for a total of 14 d (7 doses). Animals were transcardially perfused 2 d later. Animals were randomly assigned to 1 of 3 groups: 1 animal received saline only (2 ml per infusion), 3 animals received low-dose Chase (5 U ml −1 × 2 ml per infusion, total dose of 70 U over 14 d) and 3 animals received high-dose Chase (25 U ml −1 × 2 ml per infusion, total dose of 350 U over 14 d). Note that because Chase is an enzyme, it is packaged and administered according to units of enzymatic activity. For Chase, 1 U is the amount that catalyzes the conversion of 1 μmol of chondroitin sulfate A or C per minute at 37 °C and pH 8.0. The low dose was comparable to rat intrathecal studies, scaled according to cerebrospinal fluid volume. The high dose was meant to test whether better CSPG degradation could be achieved with higher Chase concentration, but showed no difference in CSPG degradation compared to the low dose (see Results). Animals were killed 2 d after the last infusion (16 d after the first infusion). Because Chase achieves its maximum digestion range within 24 h 51, 52 , this time point should reflect the extent of CSPG digestion achievable through intrathecal administration. Spinal cords with the dura intact were removed, sectioned into 1 cm blocks and fixed in 4% cold paraformaldehyde (PFA) for 24 h. Tissue was transferred to 10% glycerol/2% dimethylsulfoxide (DMSO) in PBS overnight and then transferred to 20% glycerol/2% DMSO in PBS (pH 7.4) and was stored refrigerated (2-8 °C). Tissue was sent to UCSD and sectioned in the coronal plane on a freezing microtome set at 35 µm intervals. Sections were then labeled as detailed for the primate studies.
Primate lesion surgery. Animals were sedated with 1 mg kg −1 ketamine intramuscularly and anesthetized with 1.5-2.5% isoflurane. The caudal half of the C5 dorsal lamina and the entire C6 dorsal lamina were removed. The dura was slit longitudinally along the midline and retracted gently. A surgical micro-knife was mounted on a stereotaxic arm positioned at the spinal midline midway between the C5 and C6 dorsal laminae. This rostrocaudal position corresponds to the C7 spinal cord segment. The stereotaxic manipulator was used to lower the blade through the entire dorsoventral extent of the spinal cord without severing the ventral artery. This initial cut established the medial position of the lesion. The lesion was then completed using microscissors under microscopic observation by the surgeon to ensure lesion completeness laterally and ventrally. The dura was sutured; then, the overlying muscle and skin were sutured in layers. Animals retained bowel, bladder and autonomic function after SCI. Lesion reconstructions are shown in Supplementary Fig. 7 .
Chase injections. Animals were assigned to Chase-treated or control groups according to post-lesion performance on functional tests (described later in the article) such that pretreatment functional deficits were equivalent across groups. Four weeks after SCI, the lesion site was reexposed; additional laminectomy and longitudinal dural incision were performed to expose the C7-C8-T1 spinal cord. Hand-assembled nested silica cannulae (240 and 150 µm outside diameter; Molex) were attached to a NanoFil 100 µl syringe; World Precision Instruments) filled with 20 U ml −1 chondroitinase ABC in ice-cold saline solution. This concentration of Chase is at the higher end of the spectrum of doses used in the literature 10, 17, 24, [53] [54] [55] [56] . Because Chase is an enzyme, it tends to be active on reaching a threshold activity concentration; higher concentrations are typically ineffective in generating a greater effect 10, 17, 24, [53] [54] [55] [56] . The volume injected (5 µl per site) was scaled from previous rat studies according to spinal cord cross-sectional area (monkey approximately = 10× rat). The syringe was mounted in a syringe pump attached to a stereotaxic frame and 5 µl of Chase was injected into the spinal cord parenchyma at each of 10 sites caudal to the SCI site. The first site was 1 mm caudal to the lesion border; each additional site was 1.5 mm further caudal. Each site was 0.7 mm medial to the medial edge of the dorsal root entry zone on the right side of the spinal cord. At each site, the pia mater was nicked with a 25 G needle to allow cannula entry. Chase was injected at two depths (2.5 mm and 3.5 mm; 2.5 µl each) at a rate of 0.5 µl min −1 . To minimize Chase reflux, after the second injection at each site, we waited 2 min before withdrawing the cannula. As with the initial SCI, the dura was sutured, then the overlying muscle and skin were sutured in layers. No adverse effects were observed following Chase administration.
Corticospinal tracing. CST axons were traced to assess regeneration into the graft. As described previously 45 , 6 weeks before each animal was killed (4 months after SCI), they were anesthetized and a craniotomy was performed to expose the right and left motor cortex. Using a pulled glass micropipette attached to a picospritzer (Parker Hannifin), 300 nl of the anterograde neuronal tracer BDA (10,000 MW, 10% in water; Thermo Fisher Scientific) was injected at each of 127 sites (59 different surface locations) in the left motor cortex. These sites included the motor cortex innervating the hand, arm, trunk, leg and foot. Identical injections of the anterograde tracer dextran-conjugated Alexa Fluor 488 (A488, 10,000 MW, 5% in water; Thermo Fisher Scientific) were made in the right motor cortex. After tracer injection, the excised piece of cranium was replaced, cemented in place with dental acrylic and the incision closed in layers.
Tissue processing. Animals were killed 5.5 months after SCI. Animals were deeply anesthetized and transcardially perfused with a 4% solution of PFA, and the spinal cord was dissected out of the spinal column. The spinal cord dura was removed and the spinal cord was cut in the transverse plane into 1.5-cm-long blocks as detailed previously 30 . Blocks from segments C3, C7, C8, T1 and T2 were cut into 40-µm-thick transverse sections using a freezing microtome. Tissue sections were stored at −20 °C in cryoprotectant (25% glycerine (v/v), 30% ethylene glycol (v/v) in 0.05 M phosphate buffer).
Fluorescent immunolabeling.
Transverse sections were pretreated with 50% methanol for 20 min at 22-24 °C, washed in tris-buffered saline (TBS) and blocked for 1 h in TBS containing 5% normal donkey serum and 0.25% Triton X-100. Sections were incubated in streptavidin 488 (1:400; Thermo Fisher Scientific) and/ or primary antibodies against serotonin (goat; 1:5,000; ImmunoStar, #20079, Lot #1530001), synaptophysin (mouse; 1:300; Sigma-Aldrich, #S5768, Lot #123K4879, Clone SVP38), ionized calcium-binding adapter molecule 1 (IBA1) (rabbit; 1:1,500; FUJIFILM Wako Pure Chemical Corporation, #019-19741, Lot #WDJ3047) and glial fibrillary acidic protein (chicken; 1:1,500, EnCor Biotechnology, #CPCA-GFAP, isotype 2, Lot #6701-2). Sections were washed with TBS and then incubated in A488-or A594-conjugated secondary antibodies (1:500; Thermo Fisher Scientific) for 1 h. Sections were washed with TBS, mounted on slides and coverslipped with Mowiol mounting medium (http://cshprotocols.cshlp.org/ content/2006/1/pdb.rec10255). All antibodies were used previously in monkeys 30 .
Light-level labeling. For WFA and BDA detection, sections were washed in TBS and then quenched in 0.6% H 2 O 2 in 50% methanol in TBS for 30 min. Sections were then washed with TBS and incubated overnight at 4 °C in WFA-biotin (1:1,000; reduced form; Sigma-Aldrich) or Vectastain Elite ABC solution (Vector Laboratories) and 0.25% Triton X-100 in TBS. WFA sections were washed with TBS, then incubated with Vectastain Elite ABC solution for 1 h. All sections were then washed again and developed with 3,3′-diaminobenzidine (DAB) and NiCl 2 . Sections were mounted on gelatin-subbed glass slides, dehydrated and coverslipped with DPX mounting medium (Sigma-Aldrich).
For A488, CD8, CD3 and CD45 detection, sections were washed in TBS and then quenched in 0.6% H 2 O 2 in 100% methanol in TBS for 30 min. Sections were then washed with TBS, blocked for 1 h in 5% horse serum (Lampire Biological Laboratories) and 0.25% Triton X-100 in TBS (TBS++), and incubated at 4 °C in TBS++ with rabbit anti-A488 antibody (1:5,000; Thermo Fisher Scientific, #A11094, Lot #1314344) over 2 nights (~42 h), or mouse anti-CD8 antibody (1:500; BD Pharmingen #555364, Lot #36720, Clone RPA-T8), mouse anti-CD3 antibody (1:500; BD Pharmingen #555337, Lot #M067088, Clone HIT3A) or mouse anti-CD45 antibody (1:500, BD Pharmingen #555480, Lot #50013, Clone HI30) overnight. Sections were washed in TBS, then incubated for 45 min in, as appropriate, horse anti-rabbit or horse anti-mouse ImmPRESS (1:1; Vector Laboratories) in TBS. Sections were washed again and developed with DAB and NiCl 2 . Sections were mounted on gelatin-subbed glass slides, dehydrated and coverslipped with DPX mounting medium.
For 2B6 detection, porcine tissue sections were washed in TBS and then quenched in 0.6% H 2 O 2 in TBS for 30 min. Sections were then washed with TBS, blocked for 1 h in 5% horse serum and 0.25% TBS++, and incubated at 4 °C in TBS++ with mouse antri-2B6 antibody (mouse; 1:2,000; Seikagaku #270432, Lot #06902, Clone 2-B-6; now available from Amsbio #270432-CS) overnight. Sections were washed in TBS, then incubated for 1 h in biotinylated horse anti-mouse IgG (1:200; Vector Laboratories) in TBS++. Sections were washed again with TBS, then incubated with Vectastain Elite ABC solution for 45 min. Sections were then washed again and developed with DAB and NiCl 2 . Sections were mounted on gelatin-subbed glass slides, dehydrated and coverslipped with DPX mounting medium.
Nissl substance was labeled in sections from a 1:12 series covering spinal cord segments C3, C7, C8, T1 and T2. Sections were washed in TBS, fixed in buffered 4% PFA for 1 h at room temperature, mounted on gelatin-subbed glass slides and dried overnight. Sections were then defatted in a 1:1 mixture of chloroform and ethanol, rehydrated, placed briefly in 0.25% thionin, dehydrated, cleared and coverslipped.
Quantification of axons, synapses, motor neurons and microglia. Axon density was quantified with ImageJ v.1.41c (NIH) and a custom-written script (J.J.L.), derived from previous methods (E.S.R.) 30 ; 20× images of the entire spinal cord were obtained and loaded into ImageJ. All images were corrected for brightness and contrast equally to reduce background noise. For CST axons, regions of interest (ROIs) were drawn around the right gray matter. For 5-HT-labeled raphespinal axons, ROIs were drawn around the right and left motor pools. The image was auto-thresholded, the detected fiber profiles were skeletonized (so that sum of pixels = total axon length) and measurements for each ROI were recorded in the right gray matter.
Synapse counts (colocalization of BDA and synaptophysin) were performed with 60× confocal image stacks loaded into ImageJ. Three non-overlapping image stacks were obtained in the right intermediate zone of each of four tissue sections per animal. The experimenter systematically sampled the entire image stack for clearly colocalized BDA and synaptophysin in bouton-like swellings connected to BDA-labeled axons. The number of putative synapses was divided by the volume of the image stack (approximately 900,000 µm 3 ) and converted to synapses per mm 3 . Spinal motor neurons were counted in Nissl-labeled sections at sequential rostrocaudal distances from a sample injection site on both injected and uninjected sides of the spinal cord. The number of motor neurons on the injected side was divided by the sum of the number of motor neurons on the injected and uninjected sides, such that the expected proportion was 0.5; 5-6 total sections were counted per animal (up to 1 section per x axis position).
Microglial density was quantified using IBA1 labeling. IBA1 pixel density was calculated using the ImageJ auto-thresholding function on images of the intermediate zone of the gray matter in tissue sections immediately adjacent to the injection sites (or similar regions in the C8-T1 spinal cord for uninjected animals). Tissue sections from animals in the present study were immunolabeled for IBA1 concurrently with sections from animals involved in a previous study 30 (n = 3 intact animals, n = 4 animals 2 weeks after C7 hemisection SCI and n = 3 animals 5 months after C7 hemisection SCI).
Experimenters were blind to group membership during all quantitative analyses.
Functional testing. Functional outcomes were assessed in an open field paradigm using an ordinal scale, as described in detail in Nout et al. 42 and Salegio et al. 44 . In the open field testing enclosure (1.5 × 2.1 × 3.0 m 3 ), monkeys could access perches at various levels, climb along the enclosure walls and manipulate objects containing small food rewards using dexterous hand movements. Use of each hind limb and forelimb on the tasks was rated by an observer over the 30 min observation period; video recordings allow reassessments as necessary. A total of 72 points on the scale are possible. We also rated monkeys on a 22-point forelimb subscore that focuses on arm, hand and digit use during object manipulation 42, 44 . Monkeys underwent pre-lesion baseline training, followed by three half-hour exposures per week to the enclosure to encourage activity and limb use. Performance was videotaped and rated once weekly. We compared the level of functional performance of lesioned control monkeys (n = 5) to Chase-treated monkeys (n = 6).
The ability of animals to perform fine motor functions with the affected hand were also assessed using a modified, cage-mounted Brinkman board, which required use of the affected (right) hand to retrieve small food items. This custom-made Plexiglas box is hung at the front of each animal's cage. The left hand pushes a spring-mounted lever, which moves a Plexiglas occlusion plate, giving the affected hand access to the Brinkman board under the occlusion plate. This configuration allows the animal to perform the task in the home cage and requires use of the affected hand, thereby ensuring optimal rehabilitation and functional testing. Five different boards of increasing difficulty were presented sequentially in each testing session. Difficulty was increased by: (1) increasing the depth of wells from which monkeys needed to extract the food reward; (2) altering the angle of the well relative to the monkey's position; and (3) increasing the number of reward wells (Fig. 3 ). Monkeys were scored on the number of rewards obtained from each board, the time they took to clear the board and whether they used a pincer grasp.
All functional outcomes were measured and recorded by observers blinded to treatment group.
Statistical analysis.
For statistical analysis of functional data, we employed an a priori established, blinded, data-driven statistical workflow ( Supplementary  Fig. 11 (ref. 57 )). Diagnostic analyses of raw ordinal data revealed non-normal and non-parametric features across measures; thus, non-parametric and non-linear statistical tests were used throughout. Analysis was divided into two distinct stages. First, we compiled the full behavioral data outcome matrix (animals × tests × time points) and performed non-linear PCA on the whole matrix from all animals (both treated and untreated). The principal component loadings were then examined and cross-validated to confirm that the resulting principal component scores served as legitimate multidimensional outcome metrics [58] [59] [60] . This was done in a computationally unsupervised manner by applied biostatisticians (J.R.H., A.R.F.) blind to experimental condition. Second, we performed a directed single hypothesis test (LMM; Fig. 3a) , unblinded to the effect of Chase on PC1. This staged statistical analysis approach brings together machine learning-based pattern detection (stage 1), with hypothesis testing (stage 2) to maximize outcome information without relying on multiple hypothesis testing, thereby limiting the false discovery rate. Technically, the non-linear PCA approach (stage 1) reduces the large amount of behavioral data (open field and each level of Brinkman board for each animal at each time point) into an overall integrated behavioral score, while taking into account the level of measurement of each measure (ordinal, continuous, etc.) and a wide range of possible distributions, through optimal scaling transformations and pattern detection using the alternating least squares algorithm 61 . The resulting principal components are orthogonal and, by definition, normally distributed, with the first principal component accounting for the most variance. The principal component loading reflects the correlation between each measure and the non-linear principal component. The squared factor loading for each of these measures indicates the percentage of variance in a principal component that is explained by that measure. A bootstrapping procedure was then used for internal validation of the loading pattern. The bootstrapping procedure was a non-parametric approach that resampled the dataset 1,000 times, with each iteration producing loadings from a slight variation of the original dataset. This step was followed by a pattern-matching algorithm to test the similarity between the original and bootstrapped loading patterns. After confirmation of loading pattern stability, principal component loading weights were applied to derive a principal score for each animal at each individual time point. In stage 2, we applied an LMM to assess the impact of Chase on principal component scores over time for each group, using a diagonal covariance matrix structure with each individual animal as a random factor, thereby standardizing scores for each animal according to their pre-drug baseline function. Stage 1 and stage 2 were implemented in SPSS v.25 (IBM Corporation) using the CATPCA and LMM subcommands, respectively. Repeated measures ANOVA was used to test for the main effects of time for each group in instances where data had no missing values, with sphericity assumed. CST and synapse measurements were also analyzed using an LMM, with the histological section set as a repeated measure for each animal, using a diagonal covariance matrix structure and animal as a random factor. A generalized estimating equation (GEE) model was used for the non-linear 5-HT ratio data. LMMs and GEEs are modern approaches that do not suffer from the violations of 'independence' and 'sphericity' assumptions that affect general linear modeling approaches popularized in the twentieth century 62 . Given that the LMM procedure is not bound by the assumptions of equal variance and does not assume that repeated measures are independent, the ability to model both fixed and random effects in one model thus allows for the variance (and covariance of repeated measures) to be modeled rather than assumed to be equal. For LMM procedures, the covariance matrix was specified by the structure that best fitted the data as determined by the AIC. F values and d.f. are reported for all ANOVA and LMMs (precise, fractional d.f. reported) and the Wald χ 2 value is reported for the GEE model. Effect sizes and fit metrics for each analysis are reported throughout (partial η p 2 for F tests, AIC for LMMs, QIC for GEE). Since the main effects were between only two conditions throughout, no post-hoc corrections for multiple comparisons were necessary. Statistical significance for all effects was assessed at P < 0.05. All analyses were run using SPSS v.25.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Code availability
The custom-written ImageJ scripts are available from the corresponding author upon reasonable request.
